Education
About Us
Working with TipRanks
Follow Us
RedHill Biopharma (RDHL)
NASDAQ:RDHL
RDHL Stock Chart & Stats
$1.07
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.07
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$1.01 - $8.75
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.98M
Market Cap
$3.60M
Enterprise Value$685.79K
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding3,329,857
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.27
Price to Sales (P/S)1.90
P/FCF Ratio-1.63
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $1.01 and its highest was $8.75 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $3.60M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Mar 12, 2026 which is in 107 days.
How were RedHill Biopharma’s earnings last quarter?
RedHill Biopharma released its earnings results on Sep 05, 2025. The company reported -$2.318 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.318.
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 3,329,857 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
RedHill Biopharma reported an EPS of -$2.318 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.26%.
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on creating oral drug formulations that address unmet medical needs. RedHill's core products include therapies targeting conditions such as peptic ulcers, inflammatory bowel disease, and other gastrointestinal disorders, as well as oncology treatments.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
0.54% Other Institutional Investors
99.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---